At Novelion, and our subsidiary Aegerion Pharmaceuticals, we have the opportunity to transform the lives of those affected by rare diseases and we believe that it is our duty to bring that potential to reality. With that opportunity in mind, we are pleased to fund independent medical educational programs in order to help healthcare professionals enhance their understanding of the prevention, diagnosis, and treatment of certain rare diseases.
We also aim is to be a catalyst of change, offering comprehensive support to patient communities through educational grants, corporate sponsorships, exhibit opportunities, and charitable contributions.
The mission of the Investigator-Initiated Studies (IIS) Program is to provide funding for investigator-initiated research that advances both medical and scientific knowledge in areas of interest for Novelion Therapeutics, and our subsidiary Aegerion Pharmaceuticals, which ultimately benefit patient care. We are currently reviewing proposals from independent investigators for the use of lomitapide, metreleptin and zuretinol.